XERS
$10.48
+$0.29 (2.85%)+2.85%
ClosedLoading chart...
IndexN/A
Market CapN/A
Enterprise ValueN/A
Income$-0.01B
Sales$0.06B
EmployeesN/A
P/EN/A
P/SN/A
P/BN/A
P/CN/A
EV/EBITDAN/A
EV/SalesN/A
EPS (ttm)-0.06
EarningsN/A
Gross MarginN/A
Oper. MarginN/A
Profit MarginN/A
VolumeN/A
Shs OutstandN/A
ChangeN/A
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $203.07M | $163.91M | $110.25M | $49.59M | $20.43M | $2.72M | $2.46M | $1.56M |
| Cost of Revenue | $36.83M | $28.64M | $22.63M | $13.32M | $9.33M | $1.60M | $42.00K | $4.00K |
| Gross Profit | $166.24M | $135.27M | $87.61M | $36.27M | $11.11M | $1.12M | $2.42M | $1.55M |
| Gross Margin | 81.86% | 82.52% | 79.47% | 73.14% | 54.35% | 41.11% | 98.30% | 99.74% |
| Operating Expenses | $199.88M | $179.28M | $169.55M | $151.43M | $94.65M | $123.50M | $61.77M | $28.18M |
| Operating Income | $-33.65M | $-44.01M | $-81.94M | $-115.16M | $-83.55M | $-122.38M | $-59.34M | $-26.63M |
| Operating Margin | -16.57% | -26.85% | -74.32% | -232.22% | -408.84% | -4495.96% | -2407.46% | -1711.38% |
| Net Income | $-54.84M | $-62.26M | $-94.66M | $-122.72M | $-91.14M | $-125.58M | $-60.08M | $-26.55M |
| Net Margin | -27.00% | -37.98% | -85.86% | -247.48% | -446.00% | -4613.52% | -2437.32% | -1706.56% |
| EPS (Basic) | $-0.37 | $-0.45 | $-0.70 | $-1.55 | $-2.14 | $-3.49 | $-4.99 | $-13.09 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $323.06M | $322.60M | $344.52M | $304.36M | $159.15M | $108.99M | $120.03M | $45.00M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $352.68M | $329.38M | $299.33M | $209.13M | $125.39M | $94.55M | $44.62M | $102.83M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $-29.61M | $-6.78M | $45.19M | $95.23M | $33.76M | $14.44M | $75.41M | $-57.83M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $-29.61M | $-6.78M | $45.19M | $95.23M | $33.76M | $14.44M | $75.41M | $-57.83M |
| Total Liabilities & Stockholders Equity | $323.06M | $322.60M | $344.52M | $304.36M | $159.15M | $108.99M | $120.03M | $45.00M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-54.84M | $-62.26M | $-94.66M | $-122.72M | $-91.14M | $-125.58M | $-60.08M | $-26.55M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-36.98M | $-47.02M | $-102.89M | $-102.89M | $-95.53M | $-80.56M | $-56.28M | $-24.66M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Xeris (XERS) Q2 Revenue Jumps 49%The Motley Fool Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?Zacks Investment Research Xeris Biopharma: Checking-In On One Of My 'Top Ideas'Seeking Alpha Why Xeris (XERS) Might Surprise This Earnings SeasonZacks Investment Research Xeris (XERS) Up on Licensing Deal With Amgen to Develop TepezzaZacks Investment Research Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionBenzinga Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On ThursdayBenzinga
Show 12 more stories
11 Top Penny Stocks To Buy Now According To InsidersPennyStocks Penny Stocks to Buy? 3 To Watch With Insider Trading In NovemberPennyStocks Taro Pharmaceutical (TARO) Tops Q2 Earnings EstimatesZacks Investment Research Ironwood (IRWD) Surges 7.6%: Is This an Indication of Further Gains?Zacks Investment Research 3 Penny Stocks To Buy According To Analysts, Targets Up To 1,494%PennyStocks Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023Benzinga $8M Bet On Vicarious Surgical? Check Out These 3 Penny Stocks Insiders Are Aggressively BuyingBenzinga Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research BioXcel Therapeutics, Alvotech And Other Big Stocks Moving Lower On ThursdayBenzinga Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research 5 Hot Penny Stocks To Watch With Big News This WeekPennyStocks Xeris (XERS), Horizon to Develop Ready-to-Use TeprotumumabZacks Investment Research
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Discover more
You may be interested in